biomedicina slovenica


"Doxorubicin" : 84

  1. Horvat Matej; Zadnik Vesna; Južnič Šetina Tanja; Boltežar Lučka; Pahole Goličnik Jana; Novaković Srdjan; Jezeršek Novaković Barbara
    Diffuse large B-cell lymphoma
    2018
  2. Rožman Samo; Grabnar Iztok; Novaković Srdjan; Mrhar Aleš; Jezeršek Novaković Barbara
    Population pharmacokinetics of rituximab in patients with diffuse large B-cell lymphoma and association with clinical outcome
    2017
  3. Bober Peter; Alexovic Michal; Talian Ivan; Tomkova Zuzana; Viscorova Zuzana; Benckova Maria; Andrasina Igor; Ciccocioppo Rachele; Petrovič Danijel; Adamek Mariusz; Kruzliak Peter; Sabo Jan
    Proteomic analysis of the vitamin C effect on the doxorubicin cytotoxicity in the MCF-7 breast cancer cell line
    2017
  4. Rožman Samo; Novaković Srdjan; Grabnar Iztok; Cerkovnik Petra; Jezeršek Novaković Barbara
    The impact of FcyRIIa and FcyRIIIa gene polymorphisms on responses to RCHOP chemotherapy in diffuse large B-cell lymphoma patients
    2016
  5. Savšek Lina; Roš-Opaškar Tanja
    Cerebral toxoplasmosis in a diffuse large B cell lymphoma patient
    2016
  6. Boltežar Lučka; Pintarić Karlo; Jezeršek Novaković Barbara
    Fertility in young patients following treatment for Hodgkin's lymphoma
    2016
  7. Strojnik Ksenija; Pajk Bojana; Čufer Tanja
    Neutropenia in breast cancer patients treated with neo/adjuvant chemotherapy containing docetaxel and/or epidoxorubicin
    2007
  8. Ocvirk Janja; Reberšek Martina; Škof Erik
    Randomised prospective phase II study of combination chemotherapy epidoxorubicin, cisplatin, 5-FU (ECF) versus epidoxorubicin, cisplatin, capecitabin (ECX) in patients with advanced or metastatic gastric cancer
    2007
  9. Ocvirk Janja; Reberšek Martina; Škof Erik
    Randomised prospective phase II study of combination chemotherapy epidoxorubicin, cisplatin, 5-FU (ECF) versus epidoxorubicin, cisplatin, capecitabin (ECX) in patients with advanced or metastatic gastric cancer
    2007
  10. Strojnik Ksenija; Pajk Bojana; Čufer Tanja
    Neutropenia in breast cancer patients treated with neo/adjuvant chemotherapy containing docetaxel and/or epidoxorubicin
    2007
  11. Goričar Katja; Kovač Viljem; Jazbec Janez; Zakotnik Branko; Lamovec Janez; Dolžan Vita
    Influence of the folate pathway and transporter polymorphisms on methotrexate treatment outcome in osteosarcoma
    2014
  12. Blagus Tanja; Markelc Boštjan; Čemažar Maja; Kosjek Tina; Préat Véronique; Miklavčič Damijan; Serša Gregor
    In vivo real time monitoring system of electroporation mediated control of transdermal and topical drug delivery
    2013
  13. Gregorič Brigita; Zadnik Vesna; Jezeršek-Novaković Barbara
    The diffuse large B-cell lymphoma - where do we stand now in everyday clinical practice
    [Difuzni velikocelični limfom B - današnja vsakodnevna klinična praksa]
    2012
  14. Černelč Peter; Kodre Veronika
    Ocena učinkovitosti prvega zdravljenja z bortezomibom pred avtologno presaditvijo krvotvornih matičnih celic pri diseminiranem plazmocitomu
    [Effectiveness of first treatment with bortezomib prior to autologous stem cell transplantation for multiple myeloma]
    2012
  15. Slamon Denis; Eiermann Wolfgang; Robert Nicholas; Pienkowski Tadeusz; Martin Miguel; Press Michael; Mackey John; Matos Erika; Čufer Tanja; Takač Iztok
    Adjuvant trastuzumab in HER2-positive breast cancer
    2011
  16. Thurlimann Beat; Price Karen N; Gelber Richard D; Holmberg Stig B; Crivellari Diana; Colleoni Marco; Collins John; Forbes John F; Castiglione-Gertsch Monica; Lindtner J; Eržen D; Čufer T; Červek J; Cerar O; Zakotnik B; Majdič E; Golouh R; Lamovec J; Jančar J; Vrhovec I; Kramberger M
    Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93
    2009
  17. Injac Rade; Govedarica Biljana; Radić Nataša; Bošković Marija; Perše Martina; Cerar Anton; Djordjević Aleksandar; Štrukelj Borut
    Protective effect of fullerenol C60(OH)24 on acute doxorubicin induced nephrotoxicity in rats with malignant neoplasm
    2008
  18. Injac Rade; Radić Nataša; Govedarica Biljana; Bošković Marija; Perše Martina; Cerar Anton; Djordjević Aleksandar; Štrukelj Borut
    Pre-treatment with fullerenol C60(OH)24 alleviates pulmotoxic effects of doxorubicin single dose therapy of malign neoplasma in rats
    2008
  19. Injac Rade; Perše Martina; Obermajer Nataša; Djordjević -Milić Vukosava; Prijatelj Matevž; Djordjević Aleksandar; Cerar Anton; Štrukelj Borut
    Potential hepatoprotective effects of fullerenol C60(OH)24 in doxorubicin-induced hepatotoxicity in rats with mammary carcinomas
    2008
  20. Frazier OH; Forrester MD; Gemmato C; Gregoric ID
    Urgent pump exchange for stroke resulting from a distorted HeartMate XVE inflow conduit
    2007
  21. Injac Rade; Perše Martina; Bošković Marija; Djordjević Milić Vukosava; Djordjević Aleksandar; Hvala Anastazija; Cerar Anton; Štrukelj Borut
    Cardioprotective effects of fullerenol c60(oh)24 on a single dose doxorubicin-induced cardiotoxicity in rats with malignant neoplasm
    2008
  22. Takač Iztok
    Rak jajčnikov - diagnostika in zdravljenje
    [Ovarian cancer - detection methods and treatment]
    2007
  23. Auersperg Marija; Pogačnik Ana; Kloboves-Prevodnik Veronika; Serša Gregor; Čemažar Maja
    Schedule-dependency of doxorubicin and vinblastine in EAT tumours in mice
    [Pomen različnih shem zdravljenja z deksorubicinom in vinblastinom na EAT tumorjih pri miših]
    2006
  24. Čemažar Maja; Pogačnik Ana; Kloboves-Prevodnik Veronika; Serša Gregor; Auersperg Marija
    The effect of Doxorubicin and Vinblastine in EAT tumours in CBA mice
    2006
  25. Bottomley Andrew; Biganzoli Laura; Čufer Tanja; Coleman Robert E; Coens Cornel; Efficace Fabio; Calvert Hilary Allan; Gamucci Teresa; Twelves Chris; Fargeot Pierre; Piccart Martine
    Randomized, controlled trial investigating short-term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: European organization for research and treatment of cancer breast cancer group, Investigational drug branch for breast cancer and the New drug development group study
    2004
  26. Takač Iztok; Arko Darja; Bali Robert; Čas-Sikošek Nina; Gorišek Borut
    The study "Breast cancer international research group (BCIRG) 005"
    2004
  27. Takač Iztok
    Research work at the Department of gynecologic and breast oncology of Maribor teaching hospital
    2004
  28. Jereb Berta
    Praćenje kasnih posljedica liječenja kod djece oboljele od raka
    2003
  29. Atalay G; Biganzoli L; Renard F; Paridaens R; Čufer T; Coleman R; Calvert AH; Gamucci T; Minisini A; Therasse P
    Clinical outcome of breast cancer patients with liver metastases alone in the anthracycline-taxane era: a retrospective analysis of two prospective, randomised metastatic breast cancer trials
    2003
  30. Aleman Berthe MP; Raemaekers John MM; Tirelli Umberto; Bortolus Roberto; van't Veer Mars B; Lybeert Marnix LM; Keuning Jo J; Carde Patrice; Tomšič Radka; Vovk Marjeta
    Involved-filed radiotherapy for advanced Hodgkin's lymphoma
    2003
  31. Kragelj Borut
    Kemoradioterapija invazivnih karcinomov sečnega mehurja
    2003
  32. Christen R; O'Quigley J; Howell S
    Phase 1 pharmacokinetic study of high-dose progesterone and doxorubicin
    1993
  33. Biganzoli Laura; Čufer Tanja; Bruning Peter; Coleman Robert E; Duchateau Luc; Rapoport Bernardo; Nooij Marianne; Delhaye Francois; Miles D; Sulkes Aaron
    Doxorubicin-paclitaxel: a safe regimen in terms of cardiac toxicity in metastatic breast carcinoma patients. Results from a European organization for research and treatment of cancer multicenter trial
    2003
  34. Takač Iztok
    Raziskava Breast cancer international research group - BCIRG 005
    [Study Breast cancer international research group - BCIRG 005]
    2003
  35. Černelč Peter
    Zdravljenje primarne plazmacelične levkemije
    [Treatment of primary plasma cell leukemia]
    2003
  36. Bešić N; Auersperg M; Us-Krašovec M; Hočevar M; Tomšič R
    Combined doxorubicin, vinblastine and hyperfractionated radiotherapy versus combined doxorubicin and hyperfractionated radiotherapy in anaplastic thyroid carcinoma - a comparison of survival and local control rate
    2002
  37. Biganzoli L; Čufer T; Bruning P; Coleman R; Duchateau L; Calvert AH; Gamucci T; Twelves C; Fargeot P; Epelbaum R; Lohrisch C; Piccart MJ
    Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European organization for research and treatment of cancer 10961 multicenter phase III trial
    2002
  38. Bešić N; Auersperg M; Us-Krašovec M; Tomšič R
    Local control rate in anaplastic thyroid carcinoma - a combination of doxorubicin and radiotherapy performed three days a week versus five days a week
    2000
  39. Thuerlimann B; Price KN; Castiglione M; Lindtner J; Eržen D; Čufer T; Červek J; Cerar O; Zakotnik B; Majdič E; Golouh R; Lamovec J; Jančar J; Vrhovec I; Kramberger M
    Randomized controlled trial of ovarian function suppression plus tamoxifen versus the same endocrine therapy plus chemotherapy: is chemotherapy necessary for premenopausal women with node-positive, endocrine-responsive breast cancer? First results of International breast cancer study group trial 11-93
    2001
  40. Awada A; Nooij M; Biganzoli L; Čufer T; Beek L; Batter V; Piccart MJ
    A phase I study of continuous infusion 5-fluorouracil (F-intu) in combination with gemcitabine (GEM) in patients (pts) with anthracycline- (A) refractory or A- and taxane- (T) pretreated metastatic breast cancer (MBC)
    2000
  41. Biganzoli L; Čufer T; Fargeot P; Rapoport B; Nooij M; Duchateau L; van Hoorebeeck I; Yague C; Epelbaum R; Piccart M
    Doxorubicin (A)/taxol (T): a safe regimen in terms of cardiac toxicity in the contex of an EORTC multicenter trial
    2000
  42. Biganzoli L; Čufer T; Bruning P; Coleman R; Calvert H; Gamucci T; Twelves C; di Paola E Donato; Duchateau L; Yague C
    Doxorubicin (A) / Taxol (T) versus doxorubicin /cyclophosphamide (C) as first line chemotherapy in metasttaic breast cancer (MBC): a phase III study
    2000
  43. Velenšek-Prestor V; Koželj M; Rakovec P; Jereb B
    Late cardiac damage of anthracycline therapy for acute lymphoblastic leukemia in childhood
    2000
  44. Čufer Tanja; Pfeifer Marija; Vrhovec Ivan; Frangež Robert; Kosec Marjan; Mrhar Aleš; Grabnar Iztok; Golouh Rastko; Vogrinc Sonja; Sikič Branimir Ivan
    Decreased cortisol secretion by adrenal glands perfused with the P-glycoprotein inhibitor valspodar and mitotane or doxorubicin
    2000
  45. Velenšek-Prestor Veronika; Rakovec Peter; Koželj Mirta; Jereb Berta
    Late cardiac damage of anthracycline therapy for acute lymphoblastic leukemia in childhood
    2000
  46. Skerjanec A; Sandler A; Green L; Marder P; Kuan S; Chaudhary A; Slapak C
    A phase I dose-escalating trial of LY335979, a potent multidrug-resistance modulator
    1999
  47. Gabor E; Lochner N; Wolf M; Wirth M
    Acid sensitive doxorubicin - WGA prodrugs: preparation and characterization using Caco-2 monolayers
    1999
  48. Kolarić K; Potrebica V; Roth A; Stanovnik M
    Controlles phase III clinical study of 4-epi-doxorubicin + 5-fluorouracil vs. 5-fluorouracil alone in gastric and rectosigmoid cancer
    1985
  49. Kolarić K; Potrebica V; Stanovnik M
    Controlled phase III clinical study of 4-epidoxorubicin + 5-fluorouracil versus 5-fluoruracil alone in metastatic gastric and rectosigmoid cancer
    1985
  50. Kolarić K; Potrebica V; Stanovnik M
    Controlled phase III clinical study of 4-epi-doxorubicin + 5-fluorouracil vs. 5-fluorouracil alone in metastatic gastric and rectosygmoid cancer
    1985
  51. Kolarić K; Roth A; Potrebica V; Stanovnik S
    4-epi-doxorubicin + 5-fluorouracil vs 5-fuorouracil alone in advanced gastric cancer - preliminary report of a phase III controlled clinical trial
    1984
  52. Kolarič K; Potrebica V; Červek J
    Phase-II clinical trial of 4-epi-doxorubicin in metastatic solid tumors
    1983
  53. Osmak M; Nikšić D; Brozović A; Ambriović-Ristov A; Vrhovec I; Škrk J
    Drug resistant tumor cells have increased levels of tumor markers for invasion and metastasis
    1999
  54. Zima T; Tesar V; Crkovska J; Stejskalova A; Teminova J; Nemeček K; Štipek S; Platenik J; Janebova M
    Cardioxane-ICFR-187 protects from adriamicyn-induced nephrotic syndome
    2000
  55. Osmak M; Vrhovec I; Škrk J
    Cisplatin resistant glioblastoma cells may have increased concentration of urokinase plasminogen activator and plasminogen activator inhibitor type 1
    1999
  56. Rapozzi Valentina; Comelli Marina; Mavelli Irene; Šentjurc Marjeta; Schara Milan; Perissin Laura; Giraldi Tullio
    Melatonin and oxidative damage in mice liver induced by the prooxidant antitumor drug adriamycin
    1999
  57. Rozman Ciril
    Treatment of chronic lymphocytic leukaemia and low-grade non Hodgkin's lymphomas with fludarabine
    [Zdravljenje kronične limfocitne levkemije in ne-Hodgkinovih limfomov s fludarabinom]
    1998
  58. Rapozzi Valentina; Perissin Laura; Zorzet Sonia; Comelli Marina; Mavelli Irene; Šentjurc Marjeta; Pregelj Alja; Schara Milan; Giraldi Tullio
    Bone marrow toxicity and antitumor action of adriamycin in relation to the antioxidant effects of melatonin
    [Antioksidativni efekt melatonina in njegov vpliv na mielotoksičnost in protitumorsko delovanje adriamicina]
    1998
  59. Pendas S; Jaroszeski MJ; Gilbert R; Hyacinthe M; Dang V; Hickey J; Pottinger C; Illingworth P; Heller R
    Direct delivery of chemotherapeutic agents for the treatment of hepatomas and sarcomas in rat models
    [Neposredni vnos kemoterapevtov v celice kot način zdravljenja hepatomov in sarkomov na podganah]
    1998
  60. Osmak M; Kapitanović S; Vrhovec I; Beketić-Orešković L; Jernej B; Eljuga D; Škrk J
    Characterization of human breast adenocarcinoma SK-BR-3 cells resistant to doxorubicin
    1997
  61. Nikšić D; Škrk J; Vrhovec I; Osmak M
    Characterization of human cervikal carcinoma cells resistant to doxorubicin
    1997
  62. Nikšić Daniela; Škrk Janez; Vrhovec Ivan; Osmak Maja
    Izolacija i karakterizacija humanih stanica karcinoma grlića maternice otpornih na doksorubicin
    [Establishment and characterization of human cervical carcinoma cells resistant to doxorubicin]
    1997
  63. Sonc Monika
    Protitumorne učinkovine in sekundarni tumorji kot posledica kemoterapije
    1997
  64. Osmak Maja; Beketić-Orešković Lidija; Škrk Janez; Vrhovec Ivan
    Human breast adenocarcinoma cells: alterations induced by low doses of doxorubicin
    1996
  65. Brenner Winfried; Wolf Heike; Bohuslavizki Karl H; Erdmann Karen; Koening Markus; Stauch Catherina; Clausen Malte; Henze Eberhard
    Effects of verapamil on cardiac uptake of radiolabeled doxorubicin and iodo-doxorubicin in rabbits
    1996
  66. Karrer K; Micksche M; Pridun N; Theuer W; Ulsperger E; Orel J; Eržen J; Hrabar B; Klevišar M; Debevec M; Rott T
    Surgery in SCLC as first step of multimodality treatment
    1994
  67. Karrer K; Denck H; Drings P; Orel J; Bruno MF
    Leczenie chirurgiczne uzupelnione chemoterapia wielolekowa u chorych na raka drobnokomorkowego pluca
    [Adjuvant polychemotherapy of SCLC following surgical therapy]
    1985
  68. Markovič S; Hlebanja Z; Štabuc B
    Postoperative adjuvant chemotherapy with 5-fluorouracyl, adriamycin and cisplatin (FAP) in resectable gastric cancer
    1995
  69. Torlone G; Peris K; Mazzocchetti G; Caracciolo E; Schmidt I; Chimenti S
    Cutaneous Hodgkin's disease
    1993
  70. Kolarič K; Bradamante V; Červek J; Cieslinska A; Cisarz-Filipcak E; Denisov LE; Donat D; Drosik K; Gershanovic M; Štabuc B
    A phase II trial of cardioprotection with cardioxane (ICRF-187) in patients with advanced breast cancer receiving 5-fluorouracil, doxorubicin and cyclophosphamide
    1995
  71. Konya A; Vigvary Z; Rahoty P
    Neoadjuvant intraarterial chemotherapy of malignant soft tissue tumors: a new treatment protocol
    1993
  72. Petrović D; Ferle Vidović A; Škrk J; Suhar A; Turk V
    Effects of irradiation and THP-adriamycin on the proteinase activity profiles in cultured V79 cells
    1993
  73. Auersperg M; Us-Krašovec M; Stanovnik M; Čufer T; Bešić N; Goehde W
    Role of DNA flow cytometry and cytomorphology in the search of effective chemotherapy for chemoresistant tumours (renal cell carcinoma)
    1992
  74. Ban J; Sorić J; Bistrović M; Dujmović I; Miletić Z
    Dipyridamole enhances the cytotoxicity of drugs and radiation in HeLa and V79 cells in vitro
    1992
  75. Kolarić K; Vukas D; Potrebica V
    Combination of cyclophosphamide, adriamycin and platinum (CAP) versus 5-fluorouracil, adriamycin and cyclophosphamide (FAC) as primary treatment in metastatic breast cancer: results of a prospective randomized study
    1989
  76. Roth A
    Combination of chemotherapy and irradiation: a new approach in the treatment of locally advanced esophageal cancer
    1988
  77. Lasič DD; Martin FJ
    Liposomes
    [Liposomi]
    1989
  78. Hebrang A; Vidaković Z; Drinković I; Grilec S
    Kemoembolizacija hepatoma uljnom suspenzijom citostatika
    1989
  79. Šurlan M; Gadžijev E; Pavčnik D; Pleskovič J; Klančar J; Brenčič E; Štabuc B
    Sodobni načini zdravljenja malignih tumorjev jeter
    1989
  80. Karrer K; Shields TW; Denck H; Hrabar B; Vogt-Moykopf I; Salzer GM; Rott T
    The importance of surgical and multimodality treatment for small cell bronchial carcinoma
    1989
  81. Ðorđević J; Ðorđević M
    Naša iskustva sa hormonalnom terapijom uznapredovalog karcinoma dojke
    [Our experience with hormonal therapy of advanced breast cancer]
    1988
  82. Eckhardt S; Szanto J; Cerar O; Chylak V; Hernadi Z; Hindy I; Jozsef S; Juhos E; Kolarić K; Plesničar S
    Activity of epirubicin in combination chemotherapy of advanced ovarian cancer
    1987
  83. Dangubić V; Ponomarev D; Berger A
    Kombinovano lečenje bronhogenog karcinoma malih ćelija
    [Combined therapy of small-cell bronchogenic carcinoma]
    1987
  84. Kolarić K; Potrebica V; Stanovnik M
    Controlled phase III clinical study of 4-epi-doxorubicin + 5-fluorouracil versus 5-fluorouracil alone in metastatic gastric and rectosigmoid cancer
    1986



New search      Comments      Top of page Institute for Biostatistics and Medical Informatics